Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12-65
SponsorThird Affiliated Hospital, Sun Yat-Sen University
About this trial
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
Eligibility criteria
Qualifiers
Positive hepatitis b surface antigen or hepatitis b virus DNA > 0.5 year;
Age from 12 to 65 years old;
Serum total bilirubin level > 10 times upper limit of normal;
Prothrombin time activity < 40% or prothrombin time international ratio > 1.5；
Disqualifiers
Other active liver diseases;
Hepatocellular carcinoma or other malignancy;
Pregnancy or lactation;
Human immunodeficiency virus infection or congenital immune deficiency diseases;
Trial design
Treatments tested in this trial
- Entecavir
- Tenofovir Disoproxil Fumarate
- Tenofovir Alafenamide
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov